Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global SCLC therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SCLC therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis estimated the small cell lung cancer (SCLC) therapeutics market to be worth $277.8m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 3.4% over the next eight years to reach $362.3m in 2018. The growth during 2005-2010 was primarily attributed to the launch of an oral form of Hycamtin (topotecan). The steady growth rate during the forecast period is attributed to the expected launch of Amrubicin (SM-5887) in the US and Europe for the treatment of relapse/refractory SCLC patients, as well as a weak late stage pipeline with no molecules to treat newly diagnosed patients.

Scope

The report provides information on the key drivers and challenges of the SCLC therapeutics market. Its scope includes -

• Annual data on the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for SCLC therapeutics, with historic data from 2005 to 2010 and forecasts to 2018.
• Pipeline analysis data providing information on the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for SCLC fall under major therapeutic classes such as topoisomerase II inhibitors, Pan Bcl-2 inhibitors, topoisomerase I inhibitors, IGF-R1 inhibitors/hedgehog pathway inhibitors, and tyrosine kinase inhibitors.
• Analysis of the current and future competition in the global SCLC market is provided. The key market players covered are Celgene Corporation and Cephalon Inc.
• An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics coverage, including strategic a competitor assessment, market characterization and unmet needs analysis, as well as their implications for the SCLC therapeutics market.
• Analysis of key recent licensing and partnership agreements in the SCLC therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global SCLC therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global SCLC therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global SCLC therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 IPF Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Interstitial Lung Disease
2.1.2 Idiopathic Interstitial Pneumonia
2.1.3 Idiopathic Pulmonary Fibrosis
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Primary Clinical Assessment: History and Physical Examination
2.5.2 Laboratory Tests
2.5.3 Imaging Studies
2.5.4 Other Tests
2.5.5 Procedures
2.6 Treatment and Management Options
2.6.1 Pharmacologic Treatment
2.6.2 Non Pharmacologic Treatment
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance

3 IPF Therapeutics - Market Characterization
3.1 IPF Therapeutics Market Size (2005–2010) – Global
3.2 IPF Therapeutics Market Forecast (2010–2018) – Global
3.3 IPF Therapeutics Market Size (2005–2010) – The US
3.4 IPF Therapeutics Market Forecast (2010–2018) – The US
3.5 IPF Therapeutics Market Size (2005–2010) – France
3.6 IPF Therapeutics Market Forecast (2010–2018) – France
3.7 IPF Therapeutics Market Size (2005–2010) – Germany
3.8 IPF Therapeutics Market Forecast (2010–2018) – Germany
3.9 IPF Therapeutics Market Size (2005–2010) – Italy
3.10 IPF Therapeutics Market Forecast (2010–2018) – Italy
3.11 IPF Therapeutics Market Size (2005–2010) – Spain
3.12 IPF Therapeutics Market Forecast (2010–2018) – Spain
3.13 IPF Therapeutics Market Size (2005–2010) – The UK
3.14 IPF Therapeutics Market Forecast (2010–2018) – The UK
3.15 IPF Therapeutics Market Size (2005–2010) – Japan
3.16 IPF Therapeutics Market Forecast (2010–2018) – Japan
3.17 Drivers and Barriers for the IPF Therapeutics Market
3.17.1 Drivers for the IPF Therapeutics Market
3.17.2 Barriers for the IPF Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 IPF Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the IPF Therapeutics Market
4.3.1 Pirespa/Esbriet (pirfenidone)
4.3.2 Prednisone
4.3.3 Azathioprine
4.3.4 Cyclophosphamide
4.4 Key Takeaway

5 IPF Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 IPF Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 IPF Therapeutics – Phase III Pipeline
5.3.2 IPF Therapeutics – Phase II Pipeline
5.3.3 IPF Therapeutics – Phase I Pipeline
5.3.4 IPF Market – Pre-Clinical Pipeline
5.3.5 IPF Market – Discovery Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 IPF Therapeutics Market –Clinical Pipeline by Mechanism of Action
5.5 IPF Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drug Under Clinical Development
5.6.1 BIBF-1120
5.7 Key Takeaway

6 IPF Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in IPF Therapeutics Clinical Trials

7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 IPF Therapeutics: Implications for Future Market Competition

8 IPF Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Actelion Ltd.
8.2.2 Boehringer Ingelheim GmbH
8.2.3 Celgene Corporation
8.2.4 Fibrogen, Inc.
8.2.5 InterMune, Inc.
8.2.6 Other Companies in the IPF Therapeutics Market

9 IPF Therapeutics - Licensing and Partnership Deals

10 IPF Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

List of Tables

Table 1: IPF Therapeutics - Histological and Clinical Classification of IIP
Table 2: IPF Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 3: IPF Therapeutics Market, Global, Forecasts ($m), 2010–2018
Table 4: IPF Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 5: IPF Therapeutics Market, The US, Forecasts ($m), 2010–2018
Table 6: IPF Therapeutics Market, France, Revenue ($m), 2005–2010
Table 7: IPF Therapeutics Market, France, Forecasts ($m), 2010–2018
Table 8: IPF Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 9: IPF Therapeutics Market, Germany, Forecasts ($m), 2010–2018
Table 10: IPF Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 11: IPF Therapeutics Market, Italy, Forecasts ($m), 2010–2018
Table 12: IPF Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 13: IPF Therapeutics Market, Spain, Forecasts ($m), 2010–2018
Table 14: IPF Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 15: IPF Therapeutics Market, The UK, Forecasts ($m), 2010–2018
Table 16: IPF Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 17: IPF Therapeutics Market, Japan, Forecasts ($m), 2010–2018
Table 18: IPF Therapeutics-Adverse Events Related to Pirespa
Table 19: IPF Therapeutics, Phase III Pipeline, 2011
Table 20: IPF Therapeutics, Phase II Pipeline, 2011
Table 21: IPF Therapeutics, Phase I Pipeline, 2011
Table 22: IPF Therapeutics, Pre-Clinical Pipeline, 2011
Table 23: IPF Therapeutics, Discovery Pipeline, 2011
Table 24: IPF Therapeutics, Most Promising Drugs Under Clinical Development, 2011
Table 25: IPF Therapeutics, Efficacy of BIBF-1120
Table 26: IPF Therapeutics, Clinical Trials by Country, 2011
Table 27: IPF Therapeutics - Clinical Trials by Phase, 2011
Table 28: IPF Therapeutics, Clinical Trials by Status (%), 2011
Table 29: IPF Therapeutics, Prominent Sponsors, 2011
Table 30: IPF Therapeutics, Top Companies Participating in Clinical Trials, 2011
Table 31: Actelion Ltd., Respiratory Pipeline, 2011
Table 32: Boehringer Ingelheim GmbH, Respiratory Pipeline, 2011
Table 33: Celgene Corporation, Respiratory Pipeline, 2011
Table 34: Fibrogen, Inc., Respiratory Pipeline, 2011
Table 35: InterMune, Inc., Respiratory Pipeline, 2011
Table 36: IPF Therapeutics Market, Future Players
Table 37: IPF Therapeutics, Global, Deals, 2009-2011

List of Figures

Figure 1: IPF Therapeutics - Classification of Interstitial Lung Disease
Figure 2: IPF Therapeutics - Pathophysiology
Figure 3: IPF Therapeutics - Finger Clubbing in IPF Patients
Figure 4: IPF Therapeutics – Diagnosis Of IPF
Figure 5: IPF Therapeutics - Chest Radiograph
Figure 6: IPF Therapeutics - HRCT image
Figure 7: IPF Therapeutics - Referral Pathway
Figure 8: IPF Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 9: IPF Therapeutics Market, Global, Forecast ($m), 2010–2018
Figure 10: IPF Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 11: IPF Therapeutics Market, The US, Forecast ($m), 2010–2018
Figure 12: IPF Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 13: IPF Therapeutics Market, France, Forecast ($m), 2010–2018
Figure 14: IPF Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 15: IPF Therapeutics Market, Germany, Forecast ($m), 2010–2018
Figure 16: IPF Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 17: IPF Therapeutics Market, Italy, Forecast ($m), 2010–2018
Figure 18: IPF Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 19: IPF Therapeutics Market, Spain, Forecast ($m), 2010–2018
Figure 20: IPF Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 21: IPF Therapeutics Market, The UK, Forecast ($m), 2010–2018
Figure 22: IPF Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 23: IPF Therapeutics Market, Japan, Forecast ($m), 2010–2018
Figure 24: Opportunity and Unmet Need in the IPF Therapeutics Market, 2010
Figure 25: IPF Therapeutics, Strategic Competitor Assessment, 2010
Figure 26: IPF Therapeutics – Pipeline by Phase of Development, 2011
Figure 27: IPF Therapeutics, Technology Trends Analytics Framework, 2011
Figure 28: IPF Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 29: IPF Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 30: IPF Therapeutics, Chemical Structure of BIBF-1120
Figure 31: IPF Therapeutics - Clinical Trials by Country, 2011
Figure 32: IPF Therapeutics, Clinical Trials by Phase (%), 2011
Figure 33: IPF Therapeutics, Clinical Trials by Status (%), 2011
Figure 34: IPF Therapeutics, Overall Sponsors (%), 2011
Figure 35: IPF Therapeutics, Prominent Sponsors (%), 2011
Figure 36: IPF Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 37: IPF Therapeutics Market, Drivers and Restraints, 2011
Figure 38: Implications for Future Market Competition in the IPF Market, 2011
Figure 39: IPF Therapeutics Market, Pipeline by Company, 2011
Figure 40: GlobalData Market Forecasting Model